TYK2 Inhibitors Show Impressive Efficacy for Psoriasis

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque psoriasis, with one producing a PASI90 response in 61% of patients at 52 weeks.Medscape Medical News